LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

Search

Aurinia Pharmaceuticals Inc

Closed

SectorHealthcare

7.78 -1.89

Overview

Share price change

24h

Current

Min

7.74

Max

7.81

Key metrics

By Trading Economics

Income

22M

23M

Sales

2.6M

62M

P/E

Sector Avg

30.148

50.857

EPS

0.16

Profit margin

37.371

Employees

130

EBITDA

15M

22M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+23.11% upside

Dividends

By Dow Jones

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

-29M

1.1B

Previous open

9.67

Previous close

7.78

News Sentiment

By Acuity

50%

50%

169 / 381 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Aurinia Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 cze 2025, 18:52 UTC

Earnings

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

20 cze 2025, 16:15 UTC

Acquisitions, Mergers, Takeovers

Canadian Natural Selling Control of Gas Plant to Secure Approval for Schlumberger Deal

20 cze 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

20 cze 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

20 cze 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 cze 2025, 20:13 UTC

Earnings
Acquisitions, Mergers, Takeovers

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 cze 2025, 20:11 UTC

Market Talk

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20 cze 2025, 19:56 UTC

Market Talk

Crude Oil Slips to End Week -- Market Talk

20 cze 2025, 18:35 UTC

Market Talk

Warehouse Clubs Seen Growing Market Share -- Market Talk

20 cze 2025, 18:12 UTC

Market Talk

Gold Slides to Close Shortened Week -- Market Talk

20 cze 2025, 17:56 UTC

Market Talk

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20 cze 2025, 17:50 UTC

Earnings
Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 cze 2025, 17:35 UTC

Acquisitions, Mergers, Takeovers

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20 cze 2025, 17:30 UTC

Market Talk
Earnings

Adobe's AI Headwinds Seen Fading -- Market Talk

20 cze 2025, 17:03 UTC

Earnings

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20 cze 2025, 16:50 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

20 cze 2025, 16:50 UTC

Market Talk
Earnings

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20 cze 2025, 16:44 UTC

Acquisitions, Mergers, Takeovers

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20 cze 2025, 16:40 UTC

Market Talk
Earnings

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

20 cze 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

20 cze 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 cze 2025, 16:17 UTC

Acquisitions, Mergers, Takeovers

UniCredit: ULI and UVA Are Expected to Merge in 2026

20 cze 2025, 16:17 UTC

Acquisitions, Mergers, Takeovers

UniCredit: Alessandro Santoliquido has been appointed CEO of both companies alongside his role as Head of Group Insurance

20 cze 2025, 16:05 UTC

Market Talk

Gold Futures on Track to End Week Lower Despite Haven Demand -- Market Talk

20 cze 2025, 15:56 UTC

Market Talk
Earnings

Accenture Says Federal Business Had Immaterial Impact to Growth -- Market Talk

20 cze 2025, 15:26 UTC

Market Talk

Natural Gas Slips After Streak of Higher Closes -- Market Talk

20 cze 2025, 15:25 UTC

Acquisitions, Mergers, Takeovers

Regulator Says Satisfied Sale Would Preserve Competition in Area Around Seiu Processing Plant

20 cze 2025, 15:25 UTC

Acquisitions, Mergers, Takeovers

Competition Bureau Says Canadian Natural to Sell 75% Stake in Seiu Lake Natural Gas Plant to North 40 Resources

20 cze 2025, 15:25 UTC

Acquisitions, Mergers, Takeovers

Canada Antitrust Regulation Reaches Agreement With Canadian Natural Resources Over Proposed Buy of Schlumberger JV Interest

20 cze 2025, 15:09 UTC

Market Talk

Canadian Retail Sales Show Reversal of Tariff Front-Running -- Market Talk

Peer Comparison

Price change

Aurinia Pharmaceuticals Inc Forecast

Price Target

By TipRanks

23.11% upside

12 Months Forecast

Average 9.75 USD  23.11%

High 11 USD

Low 8 USD

Based on 4 Wall Street analysts offering 12 month price targets forAurinia Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

8.1 / 8.21Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

169 / 381 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.